Brain metastasis as an isolated late recurrence in small-cell lung cancer

KOICHI KURISHIMA¹, SHINSUKE HOMMA¹, KATSUNORI KAGOHASHI², KUNIHIKO MIYAZAKI¹, MIO KAWAGUCHI¹, HIROAKI SATOH² and NOBUYUKI HIZAWA¹

¹Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba; ²Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 10-0015, Japan

Received September 16, 2013; Accepted December 11, 2013

Abstract. The brain is one of the most common sites of metastasis of small-cell lung cancer (SCLC). In this study, we reported 6 cases with isolated brain relapse of SCLC ≥1 year after the completion of the initial treatment for SCLC. Of the 6 patients, 2 had a solitary brain metastasis and 4 had ≥2 brain metastatic sites. The metastases were identified during a regular check-up computed tomography (CT) scan and were successfully treated. The median interval from the initial diagnosis to the development of brain metastasis was 16 months (range, 13-30 months). All patients received whole-brain irradiation and achieved a complete response. Only one patient developed disturbances of the higher cerebral function. The median interval from whole-brain irradiation to death or last follow-up was 33 months (range, 8-90 months). To the best of our knowledge, these are the first reported cases with isolated brain relapse of SCLC. Although a rare finding, clinicians should be alert on the possibility of such recurrence, particularly in patients who refused prophylactic cranial irradiation.

Introduction

Small-cell lung cancer (SCLC) is characterized by early and widespread metastases, despite good responsiveness to chemotherapy and chemoradiotherapy (1). Overall, ~10% of patients present with brain metastases at the time of initial diagnosis and an additional 40-50% will eventually develop brain metastases during the course of their disease (1). Brain metastases may be solitary or multiple; however, late isolated brain relapse in SCLC appears to be a rare phenomenon (2). In this study, we report 6 SCLC cases with isolated brain relapse ≥1 year following the completion of the initial treatment for SCLC, which was successfully treated.

Patients and methods

Patients and staging. The medical records and pathological reports of all patients who were diagnosed with SCLC between January, 2000 and August, 2013 at Divisions of Respiratory Medicine, Faculty of Medicine, Mito Medical Center, University of Tsukuba (Mito, Japan), were reviewed. The data collected included gender, age at diagnosis, smoking history, reason for discovery of lung cancer, histological type, clinical stage, type of treatment and survival following diagnosis. The histological classification was performed according to the World Health Organization (WHO) classification of lung tumors (3). The tumor-node-metastasis staging system was used according to the 7th edition of the American Joint Committee for Cancer staging system (4). The staging procedure was performed for all the patients using chest computed tomography (CT), brain magnetic resonance imaging (MRI), bone scan, ultrasonography and/or CT of the abdomen.

Inclusion criteria. The patients’ records were examined in order to assess the inclusion criteria as follows: i) no brain metastasis at the time of initial diagnosis; ii) brain metastasis ≥1 year following the initial diagnosis; and iii) no metastatic sites other than the brain.

This observational study conformed to the Ethics Guidelines for Clinical Studies issued by the Ministry of Health, Labor and Welfare of Japan.

Results

Patients. During the 14-year period, we identified a total of 6 patients, including 5 males and 1 female, with isolated brain metastasis as a late recurrence in SCLC in our hospitals. All patients were informed on prophylactic cranial irradiation and refused treatment. Table I shows clinical characteristics of late brain metastasis as a late recurrence in SCLC patients. The brain metastases were an incidental finding during regular check-up CT scan, without any preceding symptoms.

---

Correspondence to: Professor Hiroaki Satoh, Division of Internal Medicine, Mito Medical Center, University of Tsukuba, Miya-machi 3-2-7, Mito, Ibaraki 310-0015, Japan
E-mail: hirosato@md.tsukuba.ac.jp

Key words: isolated brain metastasis, relapse, small-cell lung cancer
The median age for diagnosis of SCLC was 66 years (range, 57-76 years).

Treatment and outcome. All patients were administered chemoradiotherapy as the initial treatment and achieved a partial or complete response. The median interval from the initial diagnosis to brain metastasis was 16 months (range, 13-30 months). Of the 6 patients, 2 had brain metastasis and 4 had ≥2 brain metastatic sites. All patients received whole-brain irradiation and achieved a complete response. Only 1 patient developed a disturbance of higher cerebral function almost 5 years after the whole-brain irradiation. The median interval from the brain metastasis to death or last follow-up was 40 months (range, 8-90 months). Overall, two patients survived for ≥5 years. One patient remains alive 38 months after the brain metastasis, whereas the remaining 5 patients eventually succumbed to SCLC.

Discussion

Late cancer relapse is a growing topic of discussion, as the disease control rates for several types of cancer have increased; therefore, patients with such cancers have a high possibility of prolonged survival. Among various malignancies, the late relapse of SCLC is a well-known but uncommon finding (2,5-7). Among SCLC patients, there have been 7 reported cases of late brain metastasis as a late recurrence in small-cell lung cancer patients. The mechanism underlying such a rare metastasis has not been elucidated. It has been hypothesized that SCLC cells metastasize at a certain time during the clinical course of the disease and they may survive at the metastatic sites, escaping from immune mechanisms and entering a long-term dormancy period, after which time they may start growing again.

Prophylactic cranial irradiation (PCI) is commonly recommended for SCLC, as it was shown to reduce the incidence of brain metastases and significantly improve overall survival in limited- and extensive-disease SCLC in patients who respond to first-line treatment (16). This treatment may increase neuropsychological syndromes and brain abnormalities indicated by CT scans (17,18). However, no significant increase in late sequelae was reported by clinical trials on patients who received PCI (16,19,20). As our patients had limited disease, we explained the indication of PCI at the time of good response to first-time treatment. However, PCI was refused for fear of the appearance of neuropsychological symptoms. Our patients received whole-brain irradiation for isolated brain metastasis at the time of diagnosis of the metastasis. Only 1 patient developed neuropsychological symptoms 5 years after the whole-brain irradiation.

As demonstrated by this study, there may be patients who may expect a long-term survival following additional therapy.
for brain metastasis. However, close follow-up is required to detect metastatic lesions as early as possible, particularly for patients who refused PCI treatment.

References